A Phase I Open Label, Multicenter, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Dose Limiting Toxicity, Safety and Pharmacokinetics of CGC-11047 [PG-11047] When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil [fluorouracil] or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma

Trial Profile

A Phase I Open Label, Multicenter, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Dose Limiting Toxicity, Safety and Pharmacokinetics of CGC-11047 [PG-11047] When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil [fluorouracil] or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Feb 2012

At a glance

  • Drugs Bevacizumab; Cisplatin; Docetaxel; Erlotinib; Fluorouracil; Folinic acid; Gemcitabine; PG 11047; Sunitinib
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 24 Feb 2012 Additional lead trial investigator (Joe Stephenson) identified as reported by ClinicalTrials.gov.
    • 24 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Jun 2011 Planned End Date added to 1 Sep 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top